Real-World check: does zepzelca hold up for tough lung cancer?

NCT ID NCT06021483

Recruiting now Knowledge-focused Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is tracking 300 people with advanced small cell lung cancer who are taking the drug Zepzelca (lurbinectedin) after their first chemotherapy stopped working. Researchers want to see how well the drug shrinks tumors and what side effects occur in everyday hospital settings. The goal is to gather real-world evidence to support safe and effective use of this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zepzelca (lurbinectedin)
What this could lead to: If successful, this study could confirm how well Zepzelca works and how safe it is in everyday medical practice for people with advanced small cell lung cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It only includes people who have already failed one chemotherapy, so findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC

Contacts and locations

Locations

Seoul National University Boramae Medical Center
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.